Developer docs
API playgroundTry for free, no card

Search company profiles

Ximbio

Full company profile

uuid000gzl1

Namestring
Ximbio
Legal namestring
Cancer Research Technology Limited
Websiteurl
ximbio.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Ximbio, operating as CancerTools.org, is the non-profit research tools arm of Cancer Research UK and functions as a global catalogue and distribution platform for cancer research reagents. Founded around 2015 and rebranded as CancerTools.org in April 2022, the platform provides scientists with access to more than 13,900 validated cancer research tools, spanning antibodies, cell lines, organoids, PDX models, mouse models, cell culture media, proteins, small molecules, and vectors. Tool provenance includes 175+ university partners across six continents, with several exclusive offerings such as the TRACERx NSCLC PDX models (UCL), the PC346C prostate cancer panel (Erasmus MC), platinum-resistant HGSC ovarian cell lines (Queen Mary University of London), and melanocyte lines from St George's University of London, as well as the proprietary Plasmax™ cell culture medium developed at the Cancer Research UK Scotland Institute (Beatson).

The platform operates under a non-profit model in which proceeds from tool sales and commercial licensing are reinvested into cancer research, with cumulative contributions of £52+ million cited on the company's website. Go-to-market combines a direct e-commerce storefront for academic and not-for-profit purchasers (with publicly listed pricing such as £598 for the OvsahoCis cell line) and a dedicated licensing team handling commercial use enquiries under multi-year, quote-based contracts. Channel and community partnerships—most notably the European Association for Cancer Research (EACR, 10,000+ members in 100+ countries) and academic institutes including UCL, Queen Mary University of London, Erasmus MC, St George's, Oxford, and the Danish Cancer Society—drive both tool contributions and customer acquisition. Distribution transitioned from ECACC to direct exclusive handling in September 2024 for several previously ECACC-supported popular cancer cell line series.

Customer segments split between academic researchers and universities (primary) and pharmaceutical and biotech companies (primary commercial segment) that require authenticated preclinical models for drug discovery. The company is registered as Cancer Research Technology Limited (company number 1626049), trading as Cancer Research Horizons, and is wholly owned by Cancer Research UK; the registered office is at 2 Redman Place, London, E20 1JQ. Headcount sits at 11–50 employees and revenue is not publicly disclosed.

Short descriptiontext

Ximbio (operating as CancerTools.org) is the non-profit research tools arm of Cancer Research UK, distributing a catalogue of 13,900+ cancer research reagents—including cell lines, PDX models, antibodies, and the proprietary Plasmax™ medium—to academic researchers and pharmaceutical companies worldwide.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cancer research reagents, cell line distribution, antibody repository, PDX mouse models, biomedical research tools
Industry1 code
PRIMARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Life Sciences Research Reagents
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model2 records
1Research Tools Sales
TypeTransaction Fee
Description

Sale of cancer research tools including cell lines, antibodies, proteins, vectors, small molecules, and other reagents to academic and commercial organisations. Tools are sold for research use only with specific licensing terms for commercial applications.

cancertools.org
2Licensing Fees
TypeLicensing Royalties
Description

Licensing revenue from commercial organisations requiring commercial use licenses to use research tools. Proceeds are reinvested into cancer research as a non-profit entity.

cancertools.org
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain
Pricing details2 tiers
1Academic/Not-for-profit pricing for cell lines
ModelTransaction based/ take rateBilling cadencePay-as-you-go
Notes

OvsahoCis Cell Line: £598.00 for academic/not-for-profit use. Products available through online checkout for qualifying organisations.

cancertools.org
2Commercial/For-profit licensing
ModelLicensing/ royaltiesBilling cadenceMulti-year contract
Notes

Commercial organisations and researchers working on commercially-sponsored academic research must contact the licensing team for commercial use licenses. Pricing is quote-based and not publicly disclosed.

cancertools.org
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Ximbio, operating as CancerTools.org, is a non-profit global platform that aggregates, authenticates, stores, and distributes cancer research tools—including antibodies, cell lines, cell culture media (Plasmax™), mouse models, PDX models, proteins, small molecules, and vectors—on behalf of researchers from 175+ university partners across six continents. Proceeds from tool sales and licensing are reinvested into cancer research under the Cancer Research UK umbrella.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • £52+ million contributed to cancer research
+3 more records
Product overview1 text field

CancerTools.org is a non-profit, global cancer-focused research tools platform and the research tools arm of Cancer Research UK. The platform offers a unified marketplace for cancer researchers to access and contribute research tools. The portfolio includes eight core product categories: Antibodies, Cell Culture Media (including Plasmax™ and Plasmax™ Glucose-Free), Cell Lines (patient-derived and engineered variants), Mouse Models, PDX Models, Proteins, Small Molecules, and Vectors. Researchers deposit tools developed in their laboratories, and CancerTools.org handles production, storage, authentication, and worldwide distribution. The platform builds on the original Ximbio platform created by CRUK approximately 7 years prior to the 2022 CancerTools.org launch. Scientists from over 175 university partners on six continents have contributed tools, and proceeds from distribution are reinvested into cancer research.

Product and service14 records
1Plasmax™ Cell Culture Medium
CategoryCell Culture Media
Description

Physiologically relevant cell culture medium formulated from 80+ components with more than 50 mirroring human plasma concentrations; used by cancer researchers for primary and established cell lines, organoids, and spheroids.

2Plasmax™ Glucose-Free
CategoryCell Culture Media
Description

Glucose-free variant of Plasmax™ supporting glucose starvation experiments, tumour microenvironment studies, and metabolic tracing with stable isotopes (e.g. 13C); preserves the 80+ original components of the standard formulation.

3Cancer Cell Lines
CategoryCell Lines
Description

Cancer cell lines covering ovarian, colorectal, bladder, breast, prostate, lung, head and neck, brain, and other cancer types; includes patient-derived and engineered variants such as platinum-resistant HGSC and anti-oestrogen resistant MCF7/TAMR lines.

4Antibodies
CategoryAntibodies
Description

Research antibodies for cancer research applications, developed by scientists from academic universities and leading cancer centres worldwide and distributed via CancerTools.org.

5PDX Models
CategoryPDX Models
Description

Patient-derived xenograft models including 44 new NSCLC models from the TRACERx study and breast cancer PDXs that recapitulate patient tumour characteristics and heterogeneity; available to the global cancer research community.

6Mouse Models
CategoryMouse Models
Description

Genetically engineered mouse models for cancer research including models for colorectal cancer, prostate cancer, and other cancer types, contributed by academic researchers.

7Proteins
CategoryProteins
Description

Recombinant proteins for cancer research applications distributed via CancerTools.org.

8Small Molecules
CategorySmall Molecules
Description

Small molecule tool compounds for cancer research and drug discovery distributed via CancerTools.org.

9Vectors
CategoryVectors
Description

Plasmid vectors including the pBABE retroviral vector system for stable gene expression and cancer research applications.

10OvsahoCis Cell Line
CategoryCell Lines
Description

Platinum-resistant high-grade serous carcinoma (HGSC) cell line derived from the Ovsaho parental line; part of a six-line platinum-resistant ovarian cancer model panel from Prof. Michelle Lockley at Queen Mary University of London.

11CovCis Cell Line
CategoryCell Lines
Description

Platinum-resistant HGSC cancer cell line derived from the Cov318 parental line; shows growth advantage in the presence of platinum therapy.

12MCF7/TAMR Series
CategoryCell Lines
Description

Anti-oestrogen resistant MCF7 breast cancer cell line series including TAMR-1, TAMR-4, TAMR-7, TAMR-8 variants resistant to tamoxifen and 164R/182R variants resistant to fulvestrant; developed by Dr. Anne Lykkesfeldt at the Danish Cancer Society.

13TRACERx NSCLC PDX Models
CategoryPDX Models
Description

44 new non-small cell lung cancer patient-derived xenograft models from the Lung TRACERx study, developed by Dr. Robert Hynds and Dr. David Pearce at UCL Cancer Institute and reflecting intratumour heterogeneity across multiple regions of primary NSCLC tumours.

14Commercial Tool Licensing Service
CategoryLicensing
Description

Licensing service for commercial and for-profit organisations requiring commercial-use licences for CancerTools research tools, managed by a dedicated licensing team with quote-based pricing and multi-year agreements.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-11-15
Description

Continued partnership enabling access to pioneering TRACERx NSCLC PDX models to the global cancer research community. CRUK Lung Cancer Centre of Excellence at UCL deposits new PDX models through CancerTools.org. Joint aim to accelerate lung cancer research and therapeutics development.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-03-27
Description

Partnership strengthened to make 68 murine melanocyte and melanoblast cell lines from Dr. Elena Sviderskaya readily available globally. SGUL and the Functional Genomics Cell Bank deposit cell lines through CancerTools.org. Partnership ongoing since December 2017.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-04-05
Description

First professional membership organisation to join the global cancer research tools collaborative. EACR has 10,000+ members in 100+ countries. Partnership designed to reach EACR members to contribute research tools developed in their laboratories for global access. CancerTools.org developed co-marketing collaboration plan benefiting EACR membership.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Source institution for Plasmax™ cell culture medium - a physiologically relevant medium that mimics human plasma. The Beatson Institute developed the Plasmax formulation as part of CRUK's research infrastructure.

5European Collection of Authenticated Cell Cultures (ECACC)
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Previously produced and supplied important cell line resources on behalf of CancerTools.org for 15 years. CancerTools now handles cell line distribution exclusively following transition.

cancertools.org
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

ATCC is the dominant global non-profit bio-resource center distributing authenticated cell lines, microbial strains, and biological materials to research and industry. Directly comparable to CancerTools.org as a centralized distributor of validated cancer research tools with a fee-for-service and licensing model.

TypeDirect peer
Description

Crown Bioscience is a global contract research organization specializing in patient-derived xenograft (PDX) models and preclinical oncology services. Closely comparable to CancerTools.org's PDX model offering (e.g., TRACERx NSCLC PDX) and serves the same pharma/biotech preclinical market.

TypeBroad incumbent
Description

Thermo Fisher offers an extensive catalog of cell lines, antibodies, media, and reagents through Gibco, Invitrogen, and Applied Biosystems brands. Broad incumbent serving the same research-tool demand as CancerTools.org, with substantially greater scale and commercial reach.

TypeBroad incumbent
Description

Merck's life science business (including Sigma-Aldrich, MilliporeSigma) provides a deep catalog of reagents, cell culture media, antibodies, and small molecules. Broad incumbent competing with CancerTools.org across multiple product categories.

TypeBroad incumbent
Description

Abcam is a global commercial leader in research antibodies and life science reagents, serving the same academic and pharma research customer base as CancerTools.org. Compares as a much larger incumbent in the antibody/antibody-related tools category that CancerTools.org also serves.

TypeDirect peer
Description

Addgene is a major non-profit plasmid repository that distributes vectors for research use and shares a similar mission-driven, community-based distribution model. Direct peer in category (plasmid/vector distribution) and comparable operating philosophy to CancerTools.org.

TypeBroad incumbent
Description

Bio-Techne is a global life science tools company offering proteins, antibodies, cell culture reagents, and exosomes. Comparable to CancerTools.org across reagent and protein categories serving academic and pharma research.

8European Collection of Authenticated Cell Cultures (ECACC)
TypeDirect peer
Description

ECACC operated as a key UK-based cell line distributor that previously supplied cancer cell lines on behalf of CancerTools.org for 15 years. Direct peer in the same scientific category, with overlap in catalog and a partnership history that makes it a clear comparable.

TypeDirect peer
Description

DSMZ is a major European non-profit cell line and biological resource collection distributing human and animal cell lines for research. Direct peer operating global catalog distribution and licensing for cancer research tools.

TypeBroad incumbent
Description

Charles River distributes research animal models and provides cell line and preclinical research services. Comparable to CancerTools.org's mouse model and PDX offerings, with overlap in pharma/biotech customers and licensing for in vivo research tools.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Ximbio

Life Sciences Research Reagentsximbio.com

Ximbio (operating as CancerTools.org) is the non-profit research tools arm of Cancer Research UK, distributing a catalogue of 13,900+ cancer research reagents—including cell lines, PDX models, antibodies, and the proprietary Plasmax™ medium—to academic researchers and pharmaceutical companies worldwide.

What Ximbio does

Ximbio, operating as CancerTools.org, is the non-profit research tools arm of Cancer Research UK and functions as a global catalogue and distribution platform for cancer research reagents. Founded around 2015 and rebranded as CancerTools.org in April 2022, the platform provides scientists with access to more than 13,900 validated cancer research tools, spanning antibodies, cell lines, organoids, PDX models, mouse models, cell culture media, proteins, small molecules, and vectors. Tool provenance includes 175+ university partners across six continents, with several exclusive offerings such as the TRACERx NSCLC PDX models (UCL), the PC346C prostate cancer panel (Erasmus MC), platinum-resistant HGSC ovarian cell lines (Queen Mary University of London), and melanocyte lines from St George's University of London, as well as the proprietary Plasmax™ cell culture medium developed at the Cancer Research UK Scotland Institute (Beatson).

The platform operates under a non-profit model in which proceeds from tool sales and commercial licensing are reinvested into cancer research, with cumulative contributions of £52+ million cited on the company's website. Go-to-market combines a direct e-commerce storefront for academic and not-for-profit purchasers (with publicly listed pricing such as £598 for the OvsahoCis cell line) and a dedicated licensing team handling commercial use enquiries under multi-year, quote-based contracts. Channel and community partnerships—most notably the European Association for Cancer Research (EACR, 10,000+ members in 100+ countries) and academic institutes including UCL, Queen Mary University of London, Erasmus MC, St George's, Oxford, and the Danish Cancer Society—drive both tool contributions and customer acquisition. Distribution transitioned from ECACC to direct exclusive handling in September 2024 for several previously ECACC-supported popular cancer cell line series.

Customer segments split between academic researchers and universities (primary) and pharmaceutical and biotech companies (primary commercial segment) that require authenticated preclinical models for drug discovery. The company is registered as Cancer Research Technology Limited (company number 1626049), trading as Cancer Research Horizons, and is wholly owned by Cancer Research UK; the registered office is at 2 Redman Place, London, E20 1JQ. Headcount sits at 11–50 employees and revenue is not publicly disclosed.

Ximbio firmographics

Firmographics
Name
Ximbio
Legal name
Cancer Research Technology Limited
Website
https://ximbio.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Ximbio (operating as CancerTools.org) is the non-profit research tools arm of Cancer Research UK, distributing a catalogue of 13,900+ cancer research reagents—including cell lines, PDX models, antibodies, and the proprietary Plasmax™ medium—to academic researchers and pharmaceutical companies worldwide.
Ownership category
akta.pro rank

Ximbio industry classification

Industry
Product category
Life Sciences Research Reagents
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)

Keywords

  • Cancer research reagents
  • Cell line distribution
  • Antibody repository
  • PDX mouse models
  • Biomedical research tools

Where Ximbio is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Ximbio business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

  1. Research Tools Sales: Sale of cancer research tools including cell lines, antibodies, proteins, vectors, small molecules, and other reagents to academic and commercial organisations. Tools are sold for research use only with specific licensing terms for commercial applications.
  2. Licensing Fees: Licensing revenue from commercial organisations requiring commercial use licenses to use research tools. Proceeds are reinvested into cancer research as a non-profit entity.

Pricing tiers

ModelBillingPrice
Transaction based/ take ratePay-as-you-goAcademic/Not-for-profit pricing for cell lines
Licensing/ royaltiesMulti-year contractCommercial/For-profit licensing

Go-to-market motion3 records

Distribution channels2 records

Marketing channels5 records

Ximbio product offering

Product offering

Core offering

Ximbio, operating as CancerTools.org, is a non-profit global platform that aggregates, authenticates, stores, and distributes cancer research tools—including antibodies, cell lines, cell culture media (Plasmax™), mouse models, PDX models, proteins, small molecules, and vectors—on behalf of researchers from 175+ university partners across six continents. Proceeds from tool sales and licensing are reinvested into cancer research under the Cancer Research UK umbrella.

Product overview

CancerTools.org is a non-profit, global cancer-focused research tools platform and the research tools arm of Cancer Research UK. The platform offers a unified marketplace for cancer researchers to access and contribute research tools. The portfolio includes eight core product categories: Antibodies, Cell Culture Media (including Plasmax™ and Plasmax™ Glucose-Free), Cell Lines (patient-derived and engineered variants), Mouse Models, PDX Models, Proteins, Small Molecules, and Vectors. Researchers deposit tools developed in their laboratories, and CancerTools.org handles production, storage, authentication, and worldwide distribution. The platform builds on the original Ximbio platform created by CRUK approximately 7 years prior to the 2022 CancerTools.org launch. Scientists from over 175 university partners on six continents have contributed tools, and proceeds from distribution are reinvested into cancer research.

Differentiator

Problem solved

Functional benefit

Products and services

  • Plasmax™ Cell Culture Medium Physiologically relevant cell culture medium formulated from 80+ components with more than 50 mirroring human plasma concentrations; used by cancer researchers for primary and established cell lines, organoids, and spheroids.
  • Plasmax™ Glucose-Free Glucose-free variant of Plasmax™ supporting glucose starvation experiments, tumour microenvironment studies, and metabolic tracing with stable isotopes (e.g. 13C); preserves the 80+ original components of the standard formulation.
  • Cancer Cell Lines Cancer cell lines covering ovarian, colorectal, bladder, breast, prostate, lung, head and neck, brain, and other cancer types; includes patient-derived and engineered variants such as platinum-resistant HGSC and anti-oestrogen resistant MCF7/TAMR lines.
  • Antibodies Research antibodies for cancer research applications, developed by scientists from academic universities and leading cancer centres worldwide and distributed via CancerTools.org.
  • PDX Models Patient-derived xenograft models including 44 new NSCLC models from the TRACERx study and breast cancer PDXs that recapitulate patient tumour characteristics and heterogeneity; available to the global cancer research community.
  • Mouse Models Genetically engineered mouse models for cancer research including models for colorectal cancer, prostate cancer, and other cancer types, contributed by academic researchers.
  • Proteins Recombinant proteins for cancer research applications distributed via CancerTools.org.
  • Small Molecules Small molecule tool compounds for cancer research and drug discovery distributed via CancerTools.org.
  • Vectors Plasmid vectors including the pBABE retroviral vector system for stable gene expression and cancer research applications.
  • OvsahoCis Cell Line Platinum-resistant high-grade serous carcinoma (HGSC) cell line derived from the Ovsaho parental line; part of a six-line platinum-resistant ovarian cancer model panel from Prof. Michelle Lockley at Queen Mary University of London.
  • CovCis Cell Line Platinum-resistant HGSC cancer cell line derived from the Cov318 parental line; shows growth advantage in the presence of platinum therapy.
  • MCF7/TAMR Series Anti-oestrogen resistant MCF7 breast cancer cell line series including TAMR-1, TAMR-4, TAMR-7, TAMR-8 variants resistant to tamoxifen and 164R/182R variants resistant to fulvestrant; developed by Dr. Anne Lykkesfeldt at the Danish Cancer Society.
  • TRACERx NSCLC PDX Models 44 new non-small cell lung cancer patient-derived xenograft models from the Lung TRACERx study, developed by Dr. Robert Hynds and Dr. David Pearce at UCL Cancer Institute and reflecting intratumour heterogeneity across multiple regions of primary NSCLC tumours.
  • Commercial Tool Licensing Service Licensing service for commercial and for-profit organisations requiring commercial-use licences for CancerTools research tools, managed by a dedicated licensing team with quote-based pricing and multi-year agreements.

Quantifiable outcome

  • £52+ million contributed to cancer research
  • +3 more outcomes

Companies that use Ximbio

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Ximbio technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Ximbio partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • University College London (UCL) / UCLBcoreStrategic or Co-development Partner · 15 November 2024Continued partnership enabling access to pioneering TRACERx NSCLC PDX models to the global cancer research community. CRUK Lung Cancer Centre of Excellence at UCL deposits new PDX models through CancerTools.org. Joint aim to accelerate lung cancer research and therapeutics development.
  • St George's University of London (SGUL)coreStrategic or Co-development Partner · 27 March 2024Partnership strengthened to make 68 murine melanocyte and melanoblast cell lines from Dr. Elena Sviderskaya readily available globally. SGUL and the Functional Genomics Cell Bank deposit cell lines through CancerTools.org. Partnership ongoing since December 2017.
  • European Association for Cancer Research (EACR)coreStrategic or Co-development Partner · 5 April 2022First professional membership organisation to join the global cancer research tools collaborative. EACR has 10,000+ members in 100+ countries. Partnership designed to reach EACR members to contribute research tools developed in their laboratories for global access. CancerTools.org developed co-marketing collaboration plan benefiting EACR membership.
  • Cancer Research UK Scotland Institute (The Beatson Institute)coreStrategic or Co-development PartnerSource institution for Plasmax™ cell culture medium - a physiologically relevant medium that mimics human plasma. The Beatson Institute developed the Plasmax formulation as part of CRUK's research infrastructure.
  • European Collection of Authenticated Cell Cultures (ECACC)minorChannel Partner/ Reseller/ DistributorPreviously produced and supplied important cell line resources on behalf of CancerTools.org for 15 years. CancerTools now handles cell line distribution exclusively following transition.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Ximbio competitors and assessment

Company assessment

Direct peers

  • ATCC (American Type Culture Collection): ATCC is the dominant global non-profit bio-resource center distributing authenticated cell lines, microbial strains, and biological materials to research and industry. Directly comparable to CancerTools.org as a centralized distributor of validated cancer research tools with a fee-for-service and licensing model.
  • Crown Bioscience: Crown Bioscience is a global contract research organization specializing in patient-derived xenograft (PDX) models and preclinical oncology services. Closely comparable to CancerTools.org's PDX model offering (e.g., TRACERx NSCLC PDX) and serves the same pharma/biotech preclinical market.
  • Addgene: Addgene is a major non-profit plasmid repository that distributes vectors for research use and shares a similar mission-driven, community-based distribution model. Direct peer in category (plasmid/vector distribution) and comparable operating philosophy to CancerTools.org.
  • European Collection of Authenticated Cell Cultures (ECACC): ECACC operated as a key UK-based cell line distributor that previously supplied cancer cell lines on behalf of CancerTools.org for 15 years. Direct peer in the same scientific category, with overlap in catalog and a partnership history that makes it a clear comparable.
  • DSMZ (Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures): DSMZ is a major European non-profit cell line and biological resource collection distributing human and animal cell lines for research. Direct peer operating global catalog distribution and licensing for cancer research tools.

Broad incumbents

  • Thermo Fisher Scientific (Life Sciences): Thermo Fisher offers an extensive catalog of cell lines, antibodies, media, and reagents through Gibco, Invitrogen, and Applied Biosystems brands. Broad incumbent serving the same research-tool demand as CancerTools.org, with substantially greater scale and commercial reach.
  • Merck / Sigma-Aldrich (Life Science): Merck's life science business (including Sigma-Aldrich, MilliporeSigma) provides a deep catalog of reagents, cell culture media, antibodies, and small molecules. Broad incumbent competing with CancerTools.org across multiple product categories.
  • Abcam: Abcam is a global commercial leader in research antibodies and life science reagents, serving the same academic and pharma research customer base as CancerTools.org. Compares as a much larger incumbent in the antibody/antibody-related tools category that CancerTools.org also serves.
  • Bio-Techne: Bio-Techne is a global life science tools company offering proteins, antibodies, cell culture reagents, and exosomes. Comparable to CancerTools.org across reagent and protein categories serving academic and pharma research.
  • Charles River Laboratories: Charles River distributes research animal models and provides cell line and preclinical research services. Comparable to CancerTools.org's mouse model and PDX offerings, with overlap in pharma/biotech customers and licensing for in vivo research tools.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Ximbio social profiles

Digital presence

Ximbio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Ximbio leadership team

Management profile

Number of profiles

Ximbio funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Ximbio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ximbio

What does Ximbio do?

Ximbio, operating as CancerTools.org, is a non-profit global platform that aggregates, authenticates, stores, and distributes cancer research tools—including antibodies, cell lines, cell culture media (Plasmax™), mouse models, PDX models, proteins, small molecules, and vectors—on behalf of researchers from 175+ university partners across six continents. Proceeds from tool sales and licensing are reinvested into cancer research under the Cancer Research UK umbrella.

Is Ximbio a public or private company?

Ximbio is a private company. It is classified as nonprofit foundation owned and is currently operating.

When was Ximbio founded?

Ximbio was founded in 2015. It employs 11 to 50 people.

Where is Ximbio based?

Ximbio is headquartered in London, United Kingdom, in the Europe region.

How does Ximbio make money?

Two revenue lines are on record. Research Tools Sales are the primary driver. The others are licensing Fees.

Who are Ximbio's main competitors?

Direct peers on record are ATCC (American Type Culture Collection), Crown Bioscience, Addgene, European Collection of Authenticated Cell Cultures (ECACC) and DSMZ (Leibniz Institute DSMZ-German Collection of Microorganisms and Cell Cultures). Broad incumbents are Thermo Fisher Scientific (Life Sciences), Merck / Sigma-Aldrich (Life Science), Abcam, Bio-Techne and Charles River Laboratories.

Does Ximbio have an API?

No public API is recorded for Ximbio.

What industry is Ximbio in?

Ximbio's product category is Life Sciences Research Reagents. Its primary akta.pro industry code is HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals